Search hospitals > Indiana > Richmond
Reid Health
Claim this profileRichmond, Indiana 47374
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Lymphoma
Conducts research for Cancer
394 reported clinical trials
2 medical researchers
Summary
Reid Health is a medical facility located in Richmond, Indiana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Lymphoma, Cancer and other specialties. Reid Health is involved with conducting 394 clinical trials across 448 conditions. There are 2 research doctors associated with this hospital, such as Howard M. Gross and Jithendra Choudary, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Howard M. GrossKettering Medical Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
134 reported clinical trials
200 drugs studied
Jithendra Choudary, MDReid Health8 years of reported clinical research
Studies Coronary Artery Disease
Studies Myocardial Ischemia
1 reported clinical trial
2 drugs studied
Clinical Trials running at Reid Health
Lung Cancer
Bladder Cancer
Prostate Cancer
Breast Cancer
Breast cancer
Esophageal cancer
Melanoma
Multiple Myeloma
Cancer
Kidney Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Reid Health?
Reid Health is a medical facility located in Richmond, Indiana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Lymphoma, Cancer and other specialties. Reid Health is involved with conducting 394 clinical trials across 448 conditions. There are 2 research doctors associated with this hospital, such as Howard M. Gross and Jithendra Choudary, MD.
Where is Reid Health located?
**Reid Health Hospital Location:**
- Address: 1100 Reid Parkway, Richmond, IN 47374.
- Directions: From downtown Richmond, head north on North 12th Street, turn right onto East Main Street, then turn left onto North 16th Street. Continue onto Chester Boulevard, then turn right onto Reid Parkway.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Reid Health, visit the Patient Financial Services office at 600 East Main, Richmond, or the Patient Advocates at 1100 Reid Parkway. Alternatively, call customer service at (765) 983-3184 or download the Financial Assistance Policy and Application at [www.ReidHealth.org/financial-assistance](http://www.ReidHealth.org/financial-assistance). For insurance inquiries, contact ClaimAid at (765) 983-3310.
What insurance does Reid Health accept?
Reid Health accepts a wide range of insurance plans, including but not limited to Aetna, Anthem, Caresource, Cigna, Humana, and UnitedHealthcare, covering commercial, Medicaid, and Medicare policies. Participation may vary by product and is subject to change. Access to services may require authorization by the primary care physician or the managed care plan.
What awards or recognition has Reid Health received?
**Reid Health, Richmond, Indiana**
- Recognized as one of the nation's "Most Wired Hospitals" for the 10th time, showcasing advanced technology use for connecting care providers and patients.
- Accredited by the Healthcare Facilities Accreditation Program (HFAP) for 15 years, affirming a dedication to quality and patient safety.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.